Compare REX AI Equity Premium Income ETF (AIPI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.3, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AIPI | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $6.79 |
52-Week Low | $32.45 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
